Global Huntington�s Disease Treatment Market Size, Share, Forecast Report, 2020-2027

Global Huntington’s Disease Treatment Market is expected to rise steadily at a CAGR of 40% during forecast period of 2018-2023.

Huntington’s Disease is a genetic disorder that causes degeneration of nerve cells in brain. The degeneration of brain cells controls movement, intellectual ability and behaviour of that person. This disease normally appears at the age of 30-50 and gets worsen within 10-25 years of time. Huntington’s disease is fatal and there is no cure for this disease.

The Global Huntington’s Disease Treatment Market is largely driven by factors such as increased adoption of novel therapeutics, increase in R&D activities, rise in target population and favourable government initiatives. The huntington’s disease pipeline will see the new development in coming years as the disease modifying drugs transforms the market landscape. Many key players in market are engaged in development of new drug products for the treatment of huntington disease. At present, more than 20 products are being studied for treatment for huntington’s disease in various stages of clinical trials.

However certain factors that can hamper the growth of this market in near future are lack of awareness regarding genetic disorders and alternative treatment plans.

Segmentation:

Global Huntington’s Disease Treatment Market is segmented into drug type, treatment and end-users. On basis of drug type the Global Huntington’s Disease Treatment Market is segmented into tetrabenazine, deutetrabenazine, selective serotonin reuptake inhibitor (SSRI), chlorpromazine,haloperidol, risperidone, olanzapine, clozapine another drug type.Based on treatment the market is further segmented into two types such as symptomatic therapy and disease-modifying therapy.On basis of end-users the market is further segmented into hospital, clinics, retail pharmacies, online pharmacies and others.
Key players:

Some of the key players in the Global Huntington’s Disease Treatment Market are Alnylam Pharmaceuticals Inc., AmpliPhi Biosciences Corp, Ceregene Inc., Lundbeck, Prana Biotechnology Limited, Teva Pharmaceutical Industries Ltd., Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Auspex Pharmaceuticals, SOM Biotech, GlaxoSmithKline, Siena Biotech, Raptor Pharmaceutical, Pfizer, Palobiofarma, Omeros Ipsen, Valeant Pharmaceuticals International Inc.

Global Huntington’s Disease Treatment Market by Drug Type:

•      Tetrabenazine
•      Deutetrabenazine
•      Selective Serotonin Reuptake Inhibitor (SSRI)
•      Chlorpromazine
•      Haloperidol
•      Risperidone
•      Olanzapine
•      Clozapine
•      Other

Global Tinea Corporis Market, by Treatment:

•      Symptomatic Therapy
•      Disease-Modifying Therapy

Global Tinea Corporis Market, by End-Users:

•       Hospital
•       Clinics
•       Online Pharmacies
•       Retail Pharmacies
•       Others